
John P Kirkpatrick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4319987/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pineal Parenchymal Tumors of Intermediate Differentiation Treated With Ventricular Radiation and Temozolomide. Advances in Radiation Oncology, 2022, 7, 100814.	1.2	5
2	Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma. Oncotarget, 2022, 13, 576-582.	1.8	4
3	Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. International Journal of Radiation Oncology Biology Physics. 2022, 114, 60-74.	0.8	33
4	Accurate Three-Dimensional Thermal Dosimetry and Assessment of Physiologic Response Are Essential for Optimizing Thermoradiotherapy. Cancers, 2022, 14, 1701.	3.7	13
5	Purposeful irradiation of the epidural space to enhance local control without compromising cord sparing in spine radiosurgery Journal of Radiosurgery and SBRT, 2022, 8, 21-26.	0.2	0
6	Comparing Outcomes of Oligometastases Treated with Hypofractionated Image-Guided Radiotherapy (HIGRT) with a Simultaneous Integrated Boost (SIB) Technique versus Metastasis Alone: A Multi-Institutional Analysis. Cancers, 2022, 14, 2403.	3.7	1
7	Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways. International Journal of Radiation Oncology Biology Physics, 2021, 110, 87-99.	0.8	86
8	Radiosurgery treatment planning using conformal arc informed volumetric modulated arc therapy. Medical Dosimetry, 2021, 46, 3-12.	0.9	4
9	Patient outcomes and tumor control in single-fraction versus hypofractionated stereotactic body radiation therapy for spinal metastases. Journal of Neurosurgery: Spine, 2021, 34, 293-302.	1.7	3
10	Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis. Frontiers in Oncology, 2021, 11, 631618.	2.8	0
11	Stereotactic Radiosurgery for Vestibular Schwannomas: Tumor Control Probability Analyses and Recommended Reporting Standards. International Journal of Radiation Oncology Biology Physics, 2021, 110, 100-111.	0.8	12
12	Hippocampal Avoidance in Multitarget Radiosurgery. Cureus, 2021, 13, e15399.	0.5	0
13	RADI-09. Clinical factors associated with death after radiotherapy for brain metastases. Neuro-Oncology Advances, 2021, 3, iii19-iii19.	0.7	0
14	Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis. CNS Oncology, 2021, 10, CNS77.	3.0	3
15	Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study. Advances in Radiation Oncology, 2021, 6, 100760.	1.2	11
16	Arteriovenous Malformation: A Real Can of Worms. International Journal of Radiation Oncology Biology Physics, 2021, 111, 851-853.	0.8	1
17	Answering the Big Clinical Questions in Brain Metastasis Management. Frontiers in Oncology, 2021, 11, 834122.	2.8	0
18	Radiation Therapy Practice Patterns for Brain Metastases in the United States in the Stereotactic Radiosurgery Era. Advances in Radiation Oncology, 2020, 5, 43-52.	1.2	36

#	Article	IF	CITATIONS
19	Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. Journal of Clinical Oncology, 2020, 38, 3773-3784.	1.6	223
20	Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. Journal of Neuro-Oncology, 2020, 147, 477-483.	2.9	4
21	Classifying Leptomeningeal Disease: AnÂEssential Element in Managing Advanced Metastatic Disease in the Central Nervous System. International Journal of Radiation Oncology Biology Physics, 2020, 106, 587-588.	0.8	6
22	Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro-Oncology, 2020, 22, 1359-1367.	1.2	49
23	Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. International Journal of Radiation Oncology Biology Physics, 2020, 107, 334-343.	0.8	81
24	Current multidisciplinary management of brain metastases. Cancer, 2020, 126, 1390-1406.	4.1	70
25	Retrospective quality metrics review of stereotactic radiosurgery plans treating multiple targets using singleâ€isocenter volumetric modulated arc therapy. Journal of Applied Clinical Medical Physics, 2020, 21, 93-99.	1.9	4
26	Hypofractionated Stereotactic Radiosurgery (HF-SRS) in the Treatment of Brain Metastases. , 2020, , 329-341.		0
27	Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). Clinical and Translational Radiation Oncology, 2019, 18, 39-45.	1.7	26
28	RADI-06. SINGLE- VERSUS MULTI-FRACTION STEREOTACTIC RADIOSURGERY FOR BRAINSTEM METASTASES. Neuro-Oncology Advances, 2019, 1, i22-i23.	0.7	0
29	TRLS-10. MITIGATING NEUROCOGNITIVE DEFICITS FROM WHOLE-BRAIN RADIOTHERAPY IN PATIENTS WITH NUMEROUS BRAIN METASTASES VIA A NOVEL SUPEROXIDE DISMUTASE MIMETIC: RATIONALE & DESIGN OF A CLINICAL TRIAL. Neuro-Oncology Advances, 2019, 1, i10-i10.	0.7	0
30	The role of chemotherapy in the treatment of central neurocytoma. CNS Oncology, 2019, 8, CNS41.	3.0	9
31	Management of Unruptured AVMs: The Pendulum Swings. International Journal of Radiation Oncology Biology Physics, 2019, 105, 687-689.	0.8	3
32	Treatment of WHO Grade 2 and 3 Gliomas With Potentially Favorable Survival: Is Monotherapy Obsolete?. International Journal of Radiation Oncology Biology Physics, 2019, 103, 533-536.	0.8	3
33	The Evolving Modern Management of Brain Metastasis. Clinical Cancer Research, 2019, 25, 6570-6580.	7.0	83
34	Can We Omit Radiation Therapy in the Treatment of Brain Metastases from Melanoma?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 473-477.	0.8	3
35	Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?. Translational Research, 2019, 208, 63-72.	5.0	13
36	Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort. Neuro-Oncology Advances, 2019, 1, vdz036.	0.7	4

#	Article	IF	CITATIONS
37	HOUT-21. CHARACTERISTICS OF SHORT-TERM SURVIVAL IN PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE ANALYSIS. Neuro-Oncology, 2019, 21, vi116-vi116.	1.2	0
38	Offer Hypofractionated SRS… If Her Performance Status Is Good. International Journal of Radiation Oncology Biology Physics, 2019, 105, 940-941.	0.8	0
39	An investigation of machine learning methods in delta-radiomics feature analysis. PLoS ONE, 2019, 14, e0226348.	2.5	40
40	Rationale for Fractionated SRS and Single SRS Session Approaches. , 2019, , 31-40.		0
41	The effect of setup uncertainty on optimal dosimetric margin in LINAC-based stereotactic radiosurgery with dynamic conformal arc technique. Journal of Radiosurgery and SBRT, 2019, 6, 55-65.	0.2	0
42	Predicting intracranial progression following stereotactic radiosurgery for brain metastases: Implications for post SRS imaging. Journal of Radiosurgery and SBRT, 2019, 6, 179-187.	0.2	1
43	The effect of MLC leaf width in single-isocenter multi-target radiosurgery with volumetric modulated arc therapy. Journal of Radiosurgery and SBRT, 2019, 6, 131-138.	0.2	5
44	Consensus Contouring Guidelines for Postoperative Completely Resected Cavity Stereotactic Radiosurgery for Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2018, 100, 436-442.	0.8	147
45	HOUT-19. TREATMENT PATTERNS, OUTCOMES, AND PROGNOSTIC INDICATORS IN ELDERLY PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE SINGLE INSTITUTION ANALYSIS. Neuro-Oncology, 2018, 20, vi117-vi117.	1.2	0
46	RARE-16. CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF YOUNG ADULTS WITH GLIOBLASTOMA AT DIAGNOSIS. Neuro-Oncology, 2018, 20, vi239-vi239.	1.2	0
47	ACTR-28. PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS. Neuro-Oncology, 2018, 20, vi17-vi17.	1.2	1
48	QOLP-13. PSYCHOSOCIAL DISTRESS IN PATIENTS WITH RECURRENT MENINGIOMAS. Neuro-Oncology, 2018, 20, vi217-vi217.	1.2	0
49	Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2018, 101, 845-853.	0.8	22
50	Proton Therapy for Brain Metastases: A Question of Value. International Journal of Radiation Oncology Biology Physics, 2018, 101, 830-832.	0.8	8
51	Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro-Oncology, 2018, 20, 1652-1660.	1.2	47
52	Assessment of concurrent stereotactic radiosurgery and bevacizumab treatment of recurrent malignant gliomas using multi-modality MRI imaging and radiomics analysis. Journal of Radiosurgery and SBRT, 2018, 5, 171-181.	0.2	7
53	Accelerated Brain DCE-MRI Using Iterative Reconstruction With Total Generalized Variation Penalty for Quantitative Pharmacokinetic Analysis: A Feasibility Study. Technology in Cancer Research and Treatment, 2017, 16, 446-460.	1.9	12
54	The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1069-1077.	0.8	58

#	Article	IF	CITATIONS
55	Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis. Neuro-Oncology, 2017, 19, 1391-1397.	1.2	28
56	Subtype-Specific Radiation Response and Therapeutic Effect of FAS Death Receptor Modulation in Human Breast Cancer. Radiation Research, 2017, 188, 169.	1.5	4
57	The radiosurgery fractionation quandary: single fraction or hypofractionation?. Neuro-Oncology, 2017, 19, ii38-ii49.	1.2	106
58	Management of GBM: a problem of local recurrence. Journal of Neuro-Oncology, 2017, 134, 487-493.	2.9	24
59	Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). International Journal of Radiation Oncology Biology Physics, 2017, 99, 812-816.	0.8	163
60	Single fraction stereotactic radiosurgery for multiple brain metastases. Advances in Radiation Oncology, 2017, 2, 555-563.	1.2	44
61	Characterization of Water-Clear Polymeric Gels for Use as Radiotherapy Bolus. Technology in Cancer Research and Treatment, 2017, 16, 923-929.	1.9	16
62	Hippocampal dose from stereotactic radiosurgery for 4 to 10 brain metastases: Risk factors, feasibility of dose reduction via re-optimization, and patient outcomes. Medical Dosimetry, 2017, 42, 310-316.	0.9	12
63	Estimating Survival in Patients With Lung Cancer and Brain Metastases. JAMA Oncology, 2017, 3, 827.	7.1	543
64	Number of tumor-infiltrating lymphocytes in breast cancer brain metastases compared to matched breast primaries Journal of Clinical Oncology, 2017, 35, 2049-2049.	1.6	4
65	Reâ€examining TGâ€142 recommendations in light of modern techniques for linear accelerator based radiosurgery. Medical Physics, 2016, 43, 5437-5441.	3.0	18
66	Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab. Melanoma Management, 2016, 3, 177-186.	0.5	10
67	Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Practical Radiation Oncology, 2016, 6, 217-225.	2.1	162
68	Embracing rejection: Immunologic trends in brain metastasis. Oncolmmunology, 2016, 5, e1172153.	4.6	33
69	The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2016, 96, 406-413.	0.8	84
70	ls a single isocenter sufficient for volumetric modulated arc therapy radiosurgery when multiple intracranial metastases are spatially dispersed?. Medical Dosimetry, 2016, 41, 285-289.	0.9	31
71	Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). Supportive Care in Cancer, 2016, 24, 4365-4375.	2.2	9
72	Brain Metastases From Melanoma: Therapy at the Crossroads. International Journal of Radiation Oncology Biology Physics, 2016, 96, 713-716.	0.8	4

#	Article	IF	CITATIONS
73	Physics considerations for single-isocenter, volumetric modulated arc radiosurgery for treatment of multiple intracranial targets. Practical Radiation Oncology, 2016, 6, 207-213.	2.1	57
74	An Active Optical Flow Model for Dose Prediction in Spinal SBRT Plans. Lecture Notes in Computational Vision and Biomechanics, 2015, , 27-35.	0.5	1
75	From active shape model to active optical flow model: a shape-based approach to predicting voxel-level dose distributions in spine SBRT. Physics in Medicine and Biology, 2015, 60, N83-N92.	3.0	16
76	ls Less, More? The Evolving Role of Radiation Therapy forÂBrain Metastases. International Journal of Radiation Oncology Biology Physics, 2015, 92, 963-966.	0.8	11
77	Radiation-Induced Malignant Gliomas: A Current Review. World Neurosurgery, 2015, 83, 530-542.	1.3	32
78	A Hypothesis: Indirect Cell Death in the Radiosurgery Era. International Journal of Radiation Oncology Biology Physics, 2015, 91, 11-13.	0.8	40
79	Defining the Optimal Planning Target Volume in Image-Guided Stereotactic Radiosurgery of Brain Metastases: Results of a Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2015, 91, 100-108.	0.8	135
80	Evaluating Radiation-induced White Matter Changes in Patients Treated with Stereotactic Radiosurgery Using Diffusion Tensor Imaging: A Pilot Study. Technology in Cancer Research and Treatment, 2014, 13, 21-28.	1.9	9
81	Stereotactic body radiotherapy: A critical review for nonradiation oncologists. Cancer, 2014, 120, 942-954.	4.1	70
82	Recurrent Malignant Gliomas. Seminars in Radiation Oncology, 2014, 24, 289-298.	2.2	40
83	Spinal Cord and Peripheral Nervous System. Medical Radiology, 2014, , 21-48.	0.1	1
84	Stereotactic ablative body radiotherapy (SABR) for effective palliation of metastases: factors affecting local control. Journal of Radiosurgery and SBRT, 2014, 3, 123-129.	0.2	1
85	Low-dose whole brain radiotherapy combined with radiosurgery for primary CNS lymphoma achieving partial response to induction methotrexate-based chemotherapy. Journal of Radiosurgery and SBRT, 2014, 3, 37-42.	0.2	3
86	The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. Journal of Neuro-Oncology, 2013, 112, 467-472.	2.9	137
87	Radiotherapy and Radiosurgery for Tumors of the Central Nervous System. Surgical Oncology Clinics of North America, 2013, 22, 445-461.	1.5	10
88	Concurrent Stereotactic Radiosurgery and Bevacizumab inÂRecurrent Malignant Gliomas: A Prospective Trial. International Journal of Radiation Oncology Biology Physics, 2013, 86, 873-879.	0.8	94
89	Oncology Scan—Low-Grade Gliomas: Predicting and Changing Outcome. International Journal of Radiation Oncology Biology Physics, 2013, 87, 234-236.	0.8	4
90	Implementing and Integrating a Clinically Driven Electronic Medical Record for Radiation Oncology in a Large Medical Enterprise. Frontiers in Oncology, 2013, 3, 69.	2.8	12

#	Article	IF	CITATIONS
91	Quantitative analysis of the factors which affect the interpatient organâ€atâ€risk dose sparing variation in IMRT plans. Medical Physics, 2012, 39, 6868-6878.	3.0	227
92	Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer. Clinical Cancer Research, 2012, 18, 1404-1414.	7.0	77
93	Stereotactic body radiotherapy treatment of extracranial metastases. Nature Reviews Clinical Oncology, 2012, 9, 654-665.	27.6	40
94	Reply to M.C. Chamberlain et al. Journal of Clinical Oncology, 2012, 30, 3316-3317.	1.6	2
95	Stereotactic Radiosurgery and Bevacizumab for Recurrent Glioblastoma Multiforme. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 695-699.	4.9	24
96	Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme. International Journal of Radiation Oncology Biology Physics, 2012, 82, 58-66.	0.8	74
97	Safety and Efficacy of Stereotactic Radiosurgery and Adjuvant Bevacizumab in Patients With Recurrent Malignant Gliomas. International Journal of Radiation Oncology Biology Physics, 2012, 82, 2018-2024.	0.8	155
98	Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2012, 82, 2111-2117.	0.8	321
99	A Quality Assurance Method that Utilizes 3D Dosimetry and Facilitates Clinical Interpretation. International Journal of Radiation Oncology Biology Physics, 2012, 84, 540-546.	0.8	39
100	In Regard to Yamamoto et al. International Journal of Radiation Oncology Biology Physics, 2012, 84, 875-876.	0.8	3
101	Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases. Journal of Clinical Oncology, 2012, 30, 419-425.	1.6	1,205
102	Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme Journal of Clinical Oncology, 2012, 30, 2094-2094.	1.6	15
103	The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM) Journal of Clinical Oncology, 2012, 30, 2090-2090.	1.6	1
104	Reply to Drs. Mulvenna and Holt. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1194-1195.	0.8	0
105	A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 414-427.	4.9	113
106	Primary Meningeal Rhabdomyosarcoma. Sarcoma, 2011, 2011, 1-4.	1.3	12
107	The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2011, 17, 4119-4124.	7.0	133
108	Estimating normal tissue toxicity in radiosurgery of the CNS: application and limitations of QUANTEC. Journal of Radiosurgery and SBRT, 2011, 1, 95-107.	0.2	16

#	Article	IF	CITATIONS
109	Radiation Dose–Volume Effects in the Spinal Cord. International Journal of Radiation Oncology Biology Physics, 2010, 76, S42-S49.	0.8	445
110	Radiation Dose–Volume Effects of Optic Nerves and Chiasm. International Journal of Radiation Oncology Biology Physics, 2010, 76, S28-S35.	0.8	438
111	Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients. International Journal of Radiation Oncology Biology Physics, 2010, 77, 655-661.	0.8	873
112	Stereotactic Radiosurgery in the Treatment of a Dural Carotid-Cavernous Fistula. Journal of Neuro-Ophthalmology, 2010, 30, 138-144.	0.8	7
113	Assessing neurotoxicity from the low-dose radiation component of radiosurgery using magnetic resonance spectroscopy. Neuro-Oncology, 2010, 12, 145-152.	1.2	10
114	6D image guidance for spinal non-invasive stereotactic body radiation therapy: Comparison between ExacTrac X-ray 6D with kilo-voltage cone-beam CT. Radiotherapy and Oncology, 2010, 95, 116-121.	0.6	73
115	The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Medical Physics, 2009, 36, 3381-3384.	3.0	74
116	Volumetric Arc Intensity–Modulated Therapy for Spine Body Radiotherapy: Comparison With Static Intensity-Modulated Treatment. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1596-1604.	0.8	117
117	Impact of collimator leaf width and treatment technique on stereotactic radiosurgery and radiotherapy plans for intra- and extracranial lesions. Radiation Oncology, 2009, 4, 3.	2.7	67
118	Dose-Dependent Effects of Radiation Therapy on Cerebral Blood Flow, Metabolism, and Neurocognitive Dysfunction. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1082-1087.	0.8	62
119	Stereotactic Body Radiotherapy for Lesions of the Spine and Paraspinal Regions. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1369-1375.	0.8	112
120	Refinement of Treatment Setup and Target Localization Accuracy Using Three-Dimensional Cone-Beam Computed Tomography for Stereotactic Body Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 73, 571-577.	0.8	41
121	Quantifying the Dosimetric Trade-Offs When Using Intensity-Modulated Radiotherapy to Treat Concave Targets Containing Normal Tissues. International Journal of Radiation Oncology Biology Physics, 2009, 73, 585-593.	0.8	4
122	ExacTrac X-ray 6 degree-of-freedom image-guidance for intracranial non-invasive stereotactic radiotherapy: Comparison with kilo-voltage cone-beam CT. Radiotherapy and Oncology, 2009, 93, 602-608.	0.6	80
123	Paraganglioma of the Head and Neck. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 304-307.	1.3	57
124	The Linear-Quadratic Model Is Inappropriate to Model High Dose per Fraction Effects in Radiosurgery. Seminars in Radiation Oncology, 2008, 18, 240-243.	2.2	442
125	Analytic Solution to Steady-State Radial Diffusion of a Substrate with First-Order Reaction Kinetics in the Tissue of a Krogh's Cylinder. Radiation Research, 2008, 169, 350-354.	1.5	5
126	Integration of Cone-Beam CT in Stereotactic Body Radiation Therapy. Technology in Cancer Research and Treatment, 2008, 7, 133-139.	1.9	34

#	Article	IF	CITATIONS
127	Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer. Biomarker Insights, 2008, 3, BMI.S570.	2.5	30
128	Temporal Onset of Hypoxia and Oxidative Stress After Pulmonary Irradiation. International Journal of Radiation Oncology Biology Physics, 2007, 68, 196-204.	0.8	134
129	Estimating the Magnitude and Field-Size Dependence of Radiotherapy-Induced Mortality and Tumor Control After Postoperative Radiotherapy For Non–Small-Cell Lung Cancer: Calculations From Clinical Trials. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1047-1052.	0.8	29
130	How Much Radiation is the Chemotherapy Worth in Advanced Head and Neck Cancer?. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1491-1495.	0.8	68
131	High-risk gestational trophoblastic neoplasia with brain metastases: Individualized multidisciplinary therapy in the management of four patients. Gynecologic Oncology, 2007, 104, 691-694.	1.4	36
132	Erythropoietin Biology in Cancer. Clinical Cancer Research, 2006, 12, 332-339.	7.0	201
133	The Effect of Darbepoetin Alfa on Growth, Oxygenation and Radioresponsiveness of a Breast Adenocarcinoma. Radiation Research, 2006, 165, 192-201.	1.5	12
134	Tumor Hypoxia and Prognosis in Human Gliomas. Cancer Journal (Sudbury, Mass), 2006, 12, 451-454.	2.0	3
135	Kinetic modeling of tumor growth and dissemination in the craniospinal axis: implications for craniospinal irradiation. Radiation Oncology, 2006, 1, 48.	2.7	1
136	Physics and Imaging for Targeting of Oligometastases. Seminars in Radiation Oncology, 2006, 16, 85-101.	2.2	31
137	Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Molecular Cancer Therapeutics, 2006, 5, 356-361.	4.1	62
138	Combined-Modality Therapy Versus Radiotherapy Alone for Treatment of Early-Stage Hodgkin's Disease: Cure Balanced Against Complications. Journal of Clinical Oncology, 2006, 24, 605-611.	1.6	61
139	Enhancement of Cancer Radiation Therapy by Use of Adenovirus-Mediated Secretable Glucose-Regulated Protein 94/gp96 Expression. Cancer Research, 2005, 65, 9126-9131.	0.9	30
140	Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. British Journal of Cancer, 2005, 93, 1350-1355.	6.4	57
141	Radiotherapy for locally recurrent prostate cancer. Clinical Advances in Hematology and Oncology, 2005, 3, 933-42.	0.3	5
142	A Novel Conditionally Replicative Adenovirus Vector Targeting Telomerase-Positive Tumor Cells. Clinical Cancer Research, 2004, 10, 1439-1445.	7.0	56
143	Enhancement of Hypoxia-Induced Tumor Cell Death <i>In vitro</i> and Radiation Therapy <i>In vivo</i> by Use of Small Interfering RNA Targeted to Hypoxia-Inducible Factor-11±. Cancer Research, 2004, 64, 8139-8142.	0.9	118
144	Modeling killing and repopulation kinetics of subclinical cancer: direct calculations from clinical data. International Journal of Radiation Oncology Biology Physics, 2004, 58, 641-654.	0.8	20

#	Article	IF	CITATIONS
145	A Mathematical Model of Tumor Oxygen and Glucose Mass Transport and Metabolism with Complex Reaction Kinetics. Radiation Research, 2003, 159, 336-344.	1.5	35
146	Low-Dose Radiation for Posttransplant Lymphoproliferative Disorder. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 210-214.	1.3	18
147	Mass and heat transfer in a circular tube with biofouling. Water Research, 1980, 14, 117-127.	11.3	20
148	Radiation therapy for gliomas. , 0, , 49-75.		0